1. Induction chemotherapy and concurrent chemoradiotherapy for larynx preservation in laryngeal and hypopharyngeal cancerPrimož Strojan, Gaber Plavc, Robert Šifrer, Simona Jereb, Boštjan Lanišnik, Marko Kokalj, Aleš Grošelj, Cvetka Grašič-Kuhar, 2025, izvirni znanstveni članek Povzetek: To test the hypothesis that clinical tumor response after a single cycle of induction chemotherapy (ICT) can reliably differentiate between chemo-/radiosensitive and resistant tumors in the larynx preservation setting. Patients and methods Treatment consisted of docetaxel/cisplatin/5-fluorouracil (TPF) ICT followed by concurrent chemoradiotherapy (cCRT) with weekly cisplatin. The response of the primary tumor was assessed by transnasal endoscopy after the first ICT cycle. Results 37/39 (95%) patients with laryngeal (46%) or hypopharyngeal (54%) carcinoma responded to one cycle of ICT, and two patients were referred for salvage surgery. Laryngectomy-free survival at 2 and 5 years was 87% and 75%, respectively. The corresponding rates for locoregional control (and also for disease-free survival) were 79% and 70% and for overall survival 92% and 82%. Conclusions Clinical assessment of tumor response to one cycle of TPF ICT serves as a valid and easy-to-use predictor of tumor sensitivity to platinum-based cCRT.
Ključne besede: induction chemotherapy, chemoradiotherapy, arynx preservation
Objavljeno v DiRROS: 16.01.2026; Ogledov: 299; Prenosov: 295
 Celotno besedilo (883,77 KB)
Gradivo ima več datotek! Več... |
2. Leiomyosarcoma of the renal vein : analysis of outcome and prognostic factors in the world case series of 67 patientsMarko Novak, Andraž Perhavec, Katherine E. Maturen, Snežana Pavlović Djokić, Simona Jereb, Darja Eržen, 2017, izvirni znanstveni članek Povzetek: Background Leiomyosarcoma is a rare malignant mesenchymal tumour. Some cases of leiomyosarcoma of the renal vein (LRV) have been reported in the literature, but no analysis of data and search for prognostic factors have been done so far. The aim of this review was to describe the LRV, to analyse overall survival (OS), local recurrence free survival (LRFS) and distant metastases free survival (DMFS) in LRV world case series and to identify significant predictors of OS, LRFS and DMFS. Methods Cases from the literature based on PubMed search and a case from our institution were included. Results Sixty-seven patients with a mean age of 56.6 years were identified; 76.1% were women. Mean tumour size was 8.9 cm; in 68.7% located on the left side. Tumour thrombus extended into the inferior vena cava lumen in 13.4%. All patients but one underwent surgery (98.5%). After a median follow up of 24 months, the OS was 79.5%. LRFS was 83.5% after a median follow up of 21.5 months and DMFS was 76.1% after a median follow up of 22 months. Factors predictive of OS in univariate analysis were surgical margins, while factors predictive of LRFS were inferior vena cava luminal extension and grade. No factors predictive of DMFS were identified. In multivariate analysis none of the factors were predictive of OS, LRFS and DMFS. Conclusions Based on the literature review and presented case some conclusions can be made. LRV is usually located in the hilum of the kidney. It should be considered in differential diagnosis of renal and retroperitoneal masses, particularly in women over the age 40, on the left side and in the absence of haematuria. Core needle biopsy should be performed. Patients should be managed by sarcoma multidisciplinary team. LRV should be surgically removed, with negative margins.
Ključne besede: leiomysarcoma, renal vein, surgery, outcomes, prognostic factors
Objavljeno v DiRROS: 24.05.2024; Ogledov: 1368; Prenosov: 812
Celotno besedilo (458,38 KB)
Gradivo ima več datotek! Več... |
3. |
4. Rentgenska in ultrazvočna anatomija dojkeMaja Marolt-Mušič, Kristijana Hertl, Maksimiljan Kadivec, Maja Podkrajšek, Simona Jereb, 2004, objavljeni znanstveni prispevek na konferenci Povzetek: Izhodišča. Mlečna žleza je parna žleza, ki ima modificirane značilnosti žleze znojnice in se razvije v podkožnem tkivu zgornje sprednje strani prsnega koša.Skupaj s kožo jo imenujemo dojka. Zaključki. V mamografskem izvidu ni pomembno, da natančno opredelimo, kakšne strukturne spremembe so v dojki prisotne, saj te predstavljajo histološko opredelitev. Pomembno je, da v izvidu opišemo, kako gosta je struktura dojke in s tem klinika opozorimo, s kakšno verjetnostjo smo izključili patološke spremembe v smislu malignega obolenja. Pri UZ preiskavi je pomemben standarden položaj preiskovanke, kar omogoča ponovljivost preiskave. Pregledovati moramo vse dele dojke, paziti moramo, da ne izpustimo določenega predela. Pomembno je, da v izvidu označimo lego lezije: kvadrant, ura in oddaljenost od mamile.
Objavljeno v DiRROS: 01.12.2023; Ogledov: 1628; Prenosov: 423
Celotno besedilo (572,41 KB) |
5. Presejanje za odkrivanje raka dojkKristijana Hertl, Miljeva Rener, Tomaž Vargazon, Maksimiljan Kadivec, Maja Podkrajšek, Maja Marolt-Mušič, Simona Jereb, Miha Čavlek, 2004, objavljeni znanstveni prispevek na konferenci Povzetek: Izhodišča. Rak dojk (RD) je zaradi visoke incidence v razvitem svetu in v Sloveniji velik zdravstveni in ekonomski problem. Redno mamografsko pregledovanje asimptomatskih žensk (presejanje oz. screening), starih 50-69 let dolgoročno zmanjša umrljivost za RD, ker odkrije raka v zgodnejši fazi. V Sloveniji presejanje ni organizirano tako kot v nekaterih evropskih državah, ampak je oportunistično, ko ženske preventivno prihajajo v centre za bolezni dojk (CBD) na pregled po priporočilu zdravnika ali po lastni želji. Za kakovost delovanja centri nimajo enotnih državnih smernic in nad njihovim delovanjem ni nadzora. Zaključki. Uspešnost presejanja je odvisna od izbora skupine primerne starosti, udeležbe, intervala med posameznimi krogi presejanja, števila projekcij, dvojnega odčitovanja, kontrole kakovosti ter rednega beleženja in analize doseženih rezultatov. Glavne pomanjkljivosti presejanja so napačno pozitivni in napačno negativni izvidi, izpostavljenost ionizirajočem sevanju ter prediagnosticiranost.
Objavljeno v DiRROS: 01.12.2023; Ogledov: 1620; Prenosov: 501
Celotno besedilo (639,35 KB) |
6. |
7. |
8. Smernice za diagnostiko, zdravljenje in sledenje bolnikov s sarkomi mehkih tkiv in kostiMarko Novak, Olga Blatnik, Jože Pižem, Tina Žagar, Monika Jagodic, Lorna Zadravec-Zaletel, Mojca Unk, Blaž Mavčič, Jerca Blazina, Snežana Pavlović Djokić, Darja Eržen, Simona Jereb, Andreja Klevišar Ivančič, Gregor Kos, Mateja Kropivnik, David Martinčič, Eva Možina, Andraž Perhavec, Marija Skoblar Vidmar, Uroš Smrdel, Marko Špiler, Danijela Štrbac, Branko Zakotnik, Katja Limpel Novak, Vladka Salapura, Žiga Snoj, 2018, strokovni članek Ključne besede: sarkomi mehkih tkiv, sarkomi kosti, diagnostika, zdravljenje
Objavljeno v DiRROS: 06.02.2019; Ogledov: 5379; Prenosov: 1566
Celotno besedilo (278,51 KB) |
9. Sarkomi : doktrinarna načela zdravljenja in klinične potiMatej Bračko, Marta Dremelj, Darja Eržen, Monika Jagodic, Simona Jereb, Eva Možina, Marko Novak, Marko Špiler, Radka Tomšič, Lorna Zadravec-Zaletel, Branko Zakotnik, 2011, strokovni članek Ključne besede: rak (medicina), sarkom, zdravljenje
Objavljeno v DiRROS: 31.08.2018; Ogledov: 5386; Prenosov: 1278
Celotno besedilo (142,01 KB) |
